On the Record · SelectQuote
SelectQuote acquisitions, on the record
The businesses SelectQuote bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
an existing chronic care management platformWord for word“On April 2, 2024, we acquired an existing chronic care management platform for an aggregate purchase price of $4.0 million, as set forth in the Membership Interest Purchase Agreement, of which $3.4 million was paid in cash at the closing of the transaction.” 10-K for 2024 | acquisition | April 2, 2024 | $4.0 million |
Express Med PharmaceuticalsWord for word“On April 30, 2021, we acquired 100% of the outstanding shares of Express Med Pharmaceuticals for an aggregate purchase price of up to $24.0 million (subject to customary adjustments), comprised of $17.5 million in cash paid at the closing of the transaction, an additional $2.5 million of holdback for indemnification claims, if any, and an earnout of up to $4.0 million, if any.” 10-K for 2024 | acquisition | April 30, 2021 | up to $24.0 million |
Simple MedsWord for word“On August 31, 2021, SelectRx acquired 100% of the outstanding equity interests of Simple Meds for an aggregate purchase price of $7.0 million (subject to customary adjustments).” 10-K for 2024 | acquisition | August 31, 2021 | $7.0 million |
a lead distribution companyWord for word“For the year ended June 30, 2023, the Company determined that impairment triggers existed for the remaining vendor relationship recognized through the acquisition of a lead distribution company in 2021, and as a result did not expect any future economic benefit to be derived from this relationship as the relationship was terminated.” 10-K for 2024 | acquisition | 2021 | — |
existing chronic care management platform (used to launch SPM)Word for word“In 2024, we launched SPM, via a $4.0 million acquisition of an existing chronic care management platform, which offers providers, payers, and Accountable Care Organizations scalable, technology-enhanced services for patients living with chronic conditions.” 10-K for 2025 | acquisition | In 2024 | $4.0 million |
two boutique pharmaceutical operations, now SelectRxWord for word“We entered the prescription medication market in 2021 through our acquisition of two boutique pharmaceutical operations, now SelectRx.” 10-K for 2025 | acquisition | 2021 | — |
InsideResponse, an online lead generation businessWord for word“During the year ended June 30, 2025, we recorded a $4.2 million noncash impairment charge related to our acquisition in 2020 of InsideResponse, an online lead generation business.” 10-K for 2025 | acquisition | 2020 | — |
Express MedWord for word“Year Ended June 30, 2023 —Net cash used in financing activities of $29.3 million was primarily due to $10.1 million of debt issuance costs related to the Fourth Amendment, $17.8 million of principal payments on the Term Loans, and $2.4 million of holdback remitted as part of the Express Med acquisition, partially offset by $1.2 million in proceeds from common stock options exercised and the employee stock purchase plan.” 10-K for 2025 | acquisition | — | $2.4 million of holdback |
an existing chronic care management platform (SPM)Word for word“In 2024, we launched SPM, via a $4.0 million acquisition of an existing chronic care management platform, which offers providers, payers, and Accountable Care Organizations scalable, technology-enhanced services for patients living with chronic conditions.” 10-K for 2026 | acquisition | 2024 | $4.0 million |
two boutique pharmaceutical operations (SelectRx)Word for word“We entered the prescription medication market in 2021 through our acquisition of two boutique pharmaceutical operations, which are organized as wholly-owned corporate subsidiaries operating under the SelectRx brand.” 10-K for 2026 | acquisition | 2021 | — |
InsideResponseWord for word“During the year ended June 30, 2025, we recorded a $4.2 million noncash impairment charge related to our acquisition in 2020 of InsideResponse, an online lead generation business.” 10-K for 2026 | acquisition | 2020 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2018-06-30 | $0 | — |
| 2019-06-30 | $0 | — |
| 2020-06-30 | $35.8 million | — |
| 2021-06-30 | $41 million | — |
| 2022-06-30 | $6.9 million | $5.7 million |
| 2023-06-30 | $0 | — |
| 2024-06-30 | $3.4 million | — |
| 2025-06-30 | $0 | — |
Deal filings since 2016
- 2026-01-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-07-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-02-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-10-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-10-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-08-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-12-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-11-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-02-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from SelectQuote’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-08-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.